コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Hib antibody levels were protective in >99% of those sur
2 Hib conjugated to the carrier proteins CRM(197) and teta
3 Hib disease can be almost completely eliminated through
4 Hib IgG was associated with age at third immunization (P
5 Hib immunization was introduced in Kenyan infants in 200
6 Hib PS binding of the recombinant Fabs was evaluated qua
7 Hib-CRM(197) induced a rapid increase in CRM(197)-specif
8 Hib-CRM(197) induced PS and CRM(197) antibodies, vigorou
9 Hib-meningococcal outer membrane protein complex (OMPC)
10 Hib-OMPC is unique among glycoconjugate vaccines by enga
11 Hib-OMPC was significantly less immunogenic in TLR2 KO m
12 effect on Hib immunogenicity of combining 2 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) wi
13 ifBC genes were detected in 109 of 170 (64%) Hib strains and in 46 of 162 (28%) NTHi isolates (P = 0.
16 dually with an Fd region known to generate a Hib PS-combining site when paired with an A2-Arg(95a)-Jk
17 B cells were measured before a booster of a Hib-serogroup C meningococcal (MenC) conjugate vaccine a
18 ion against Hib disease wane over time after Hib vaccination at 2, 3, and 4 months of age without a b
19 ibody levels and clinical protection against Hib disease wane over time after Hib vaccination at 2, 3
22 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) with diphtheria-TT-acellular pertussis (DTaP)(
24 n immunodeficiency virus (HIV) infection and Hib vaccination status were determined for children with
25 nt serum antibody responses against MenC and Hib could be elicited by inl immunization in combination
26 umoniae, nontyphoidal salmonellae (NTS), and Hib were the most frequently isolated pathogens, and hav
33 tibody levels in children aged <5 years, and Hib vaccine coverage and timing in children aged 1 to <2
34 compared with two or three doses of another Hib vaccine (conditional odds ratio 6.77 [95% CI 3.26-14
41 variable region gene sequences encoding anti-Hib PS mAbs of infants immunized with Hib oligosaccharid
43 previously defined cross-reactive human anti-Hib PRP idiotypes and was biased towards lambda light-ch
44 tand these age-related changes in human anti-Hib PS immune responses we determined the variable regio
48 ne A2 is used to encode the majority of anti-Hib Abs, and these are the highest affinity anti-Hib Abs
50 ages 2, 3, and 4 months showed reduced anti-Hib polysaccharide IgG (geometric mean concentration [GM
53 inct immunologic characteristics of the anti-Hib PS responses in young children immunized with other
55 ne or with Hib and DTaP-based vaccines; anti-Hib capsular polysaccharide IgG, poly-ribosyl-ribitol-ph
57 Avidity differed between infants with anti-Hib-PS IgG antibody <1 or >1 microg/mL postprimary serie
58 philus influenzae b oligosaccharide antigen (Hib) and the Streptococcus pneumoniae antigen phosphocho
59 of TLR2 by Hib-OMPC was MyD88 dependent, as Hib-OMPC-induced TNF production was ablated in MyD88 kno
61 zed with DTaP5/IPV/Haemophilus influenzae b (Hib-TT) vaccine at 2-3-4 months, 13-valent pneumococcal
62 mophilus influenzae strains, one serotype b (Hib) and two nonencapsulated b capsule-negative variants
63 on of the Haemophilus influenzae serotype b (Hib) conjugate vaccine into national immunization has le
65 ne containing Haemophilus influenzae type b (Hib) and group C meningococcal polysaccharides, as well
69 umoniae), and Haemophilus influenzae type b (Hib) are three most common pathogens accounting for most
71 ponses to the Haemophilus influenzae type b (Hib) component of acellular pertussis-containing combina
72 us (IPV), and Haemophilus influenzae type b (Hib) conjugate vaccine (DTaP-IPV-Hib) among children wit
75 October 1992, Haemophilus influenzae type b (Hib) conjugate vaccine was introduced to infants in the
77 nogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines and the effect on Hib immunogeni
78 spread use of Haemophilus influenzae type b (Hib) conjugate vaccines has nearly eradicated invasive H
79 aride (PS) of Haemophilus influenzae type b (Hib) covalently linked to carrier proteins, unlike pure
82 e of invasive Haemophilus influenzae type b (Hib) disease has significantly decreased since the intro
87 dy avidity to Haemophilus influenzae type b (Hib) polysaccharide (PS) was assessed in infants vaccina
88 ve shown that Haemophilus influenzae type b (Hib) polysaccharide conjugate vaccines can reduce nasoph
89 mmunized with Haemophilus influenzae type b (Hib) PS conjugate vaccine varies with age and Ag formula
90 to compare the genome of a virulent type b (Hib) strain with that of the laboratory-passaged Rd KW20
91 troduction of Haemophilus influenzae type b (Hib) vaccination and the rollout of antiretroviral thera
92 troduction of Haemophilus influenzae type b (Hib) vaccination of children has led to a decline in inc
93 schedule for Haemophilus influenzae type b (Hib) vaccination of infants in the United Kingdom consis
94 icacy of the conjugate H. influenzae type b (Hib) vaccine was the misidentification of isolates as se
95 uce conjugate Haemophilus influenzae type b (Hib) vaccine, which, as in other developing countries bu
97 ction against Haemophilus influenzae type b (Hib), a rapidly invading encapsulated bacteria, is depen
98 me), invasive Haemophilus influenzae type b (Hib), acute hepatitis B, hepatitis A, varicella, Strepto
100 xtracted from Haemophilus influenzae type b (Hib), and the corresponding glycoconjugate made by conju
101 C (MenC) and Haemophilus influenzae type B (Hib), both of which are conjugated to the nontoxic mutan
103 otect against Haemophilus influenzae type b (Hib), serogroup C Neisseria meningitidis, and multiple c
111 b to the human nasopharynx is facilitated by Hib pili, filaments expressed on the bacterial surface.
115 ncentration and the frequency of circulating Hib-specific memory B cells were measured before a boost
121 in older children; and coverage of conjugate Hib vaccination was high (91% having 3 doses at 1-2 year
122 ion immunity after introduction of conjugate Hib vaccine in infancy without a booster dose in Kenya.
124 he vaccine is made by chemically conjugating Hib capsular polysaccharide to the outer membrane protei
126 econd year of life on the basis of declining Hib antibody concentrations after the primary series.
129 patients in the rituximab group demonstrated Hib killing (2 of 14 [14%], 5 of 6 [83%], P < .05).
132 In 1996, after switching to a different Hib conjugate vaccine, DTP-HbOC (which combines diphther
134 doses of their infant primary course as DTaP-Hib, compared with two or three doses of another Hib vac
135 ertussis-Haemophilus influenzae type b (DTaP-Hib) conjugate vaccines, 105 infants born at <32 weeks'
139 us influenzae type b (DTP/Hib; group 1), DTP/Hib and 7VPnC (group 2), or DTP and 7VPnC/Hib (group 3)
140 pertussis/Haemophilus influenzae type b (DTP/Hib; group 1), DTP/Hib and 7VPnC (group 2), or DTP and 7
141 In industrialized countries with established Hib vaccination programs, however, little is known about
143 to contribute to the repertoire, we examined Hib PS binding to a series of recombinant Fab fragments
145 of mAbs from children have high affinity for Hib PS, and the overall variable region gene repertoire
146 As with the recently published finding for Hib-TT complexes, it is the carbohydrate component that
147 pecific BCR sequences have been reported for Hib and TT, which made a vaccine containing these two Ag
150 against the C terminus of HifD and HifE from Hib strain Eagan bound to HifD and HifE proteins, respec
151 Amino acid sequence analysis of pilins from Hib pili and from P-pili expressed on uropathogenic Esch
152 105 infants born at <32 weeks' gestation had Hib IgG geometric mean concentrations (GMCs) and MCC ser
154 nus-whole cell pertussis vaccines with HbOC [Hib oligosaccharide CRM197]), cases of invasive Hib dise
155 rn immunoblot analysis of immunoprecipitated Hib pili demonstrated that HifD and HifE copurified with
159 eletion of the gene encoding for PH (lph) in Hib and Hif significantly reduced the interaction betwee
160 decreased after the initiation of an infant Hib vaccine program, perhaps by decreasing Hib carriage
167 nd microbiological surveillance for invasive Hib disease (primarily meningitis) in the Western Region
168 NTS: Culture-based surveillance for invasive Hib disease at Kilifi District Hospital from 2000 throug
171 an 5 years, the annual incidence of invasive Hib disease 1 year before and 1 and 3 years after vaccin
173 study describes the epidemiology of invasive Hib disease in England and Wales during 2000-2012 and th
175 oligosaccharide CRM197]), cases of invasive Hib disease increased, suggesting ongoing Hib transmissi
178 the carriers and caused 80% of the invasive Hib disease that occurred during April 1996-March 1997.
179 person-years) vs the third dose of DTaP-IPV-Hib (rate, 12.4 per 100 person-years) as the most recent
180 equently received the third dose of DTaP-IPV-Hib (rate, 12.8 per 100 person-years) after MMR, the IRR
182 receipt of live MMR vs inactivated DTaP-IPV-Hib as the most recent vaccine was associated with a low
184 the alternating limb group received DTaP-IPV-Hib in the left leg at 2 months and in the right leg at
186 mong 1- to 2-year-olds who received DTaP-IPV-Hib vaccine versus historical comparators (relative risk
187 sed risk was detected among 149,337 DTaP-IPV-Hib vaccinees versus historical comparators for any outc
188 tember 2008-January 2011 to compare DTaP-IPV-Hib vaccinees with historical recipients of other DTaP-c
190 and Haemophilus influenzae type b (DTaP-IPV-Hib) administered at ages 3, 5, and 12 months and MMR at
191 zae type b (Hib) conjugate vaccine (DTaP-IPV-Hib) among children within the Vaccine Safety Datalink p
192 influenzae type b combined vaccine (DTaP-IPV-Hib) at 2, 3, and 4 months of age, and the pneumococcal
194 eceived MMR after the third dose of DTaP-IPV-Hib, MMR (rate, 8.9 per 100 person-years) vs the third d
195 cine repertoire identified a number of known Hib-specific sequences but only one previously described
196 immunogenic in TLR2 KO mice, inducing lower Hib PS IgG and IgM titers compared with those in wild-ty
197 e every year from 2009 to 2012, and measured Hib antibody concentrations in five cross-sectional samp
199 ted more to piliated Hib than to nonpiliated Hib or to a mutant containing a hifE gene insertion.
200 accines by engaging TLR2, and the ability of Hib-OMPC to elicit protective levels of Abs after one do
201 ict the effect of combined administration of Hib and DTaP vaccines on Hib immunogenicity and would be
202 ifE of strain Eagan inhibited the binding of Hib to human erythrocytes but did not inhibit the bindin
203 countries include a fourth dose (booster) of Hib vaccine in the second year of life on the basis of d
205 3 and December 2001, a total of 443 cases of Hib infection occurred in children eligible for vaccinat
208 , however, suggesting that a booster dose of Hib vaccine following infant vaccination is not essentia
209 ars following infant priming with 3 doses of Hib conjugate vaccine, anti-PRP IgG geometric mean conce
211 sons for this increase, the effectiveness of Hib conjugate vaccine was estimated by use of the screen
212 ity data were used for national estimates of Hib meningitis and non-pneumonia, non-meningitis disease
213 ly correlated with the relative frequency of Hib-specific sequences, indicating that the postvaccinat
220 elop estimates of incidence and mortality of Hib meningitis and serious non-pneumonia, non-meningitis
221 haryngeal carriage is low and the profile of Hib antibodies suggests that protection wanes only after
223 Kenya, use of a three-dose primary series of Hib vaccine without a booster dose has resulted in a sig
224 007 to 2010 was complemented with studies of Hib carriage in children aged 1 to <2 years, Hib antibod
225 omprehensive literature search of studies of Hib disease incidence, case-fatality ratios, age distrib
230 ic health priority in Africa because data on Hib disease burden and vaccine effectiveness are scarce.
231 b (Hib) conjugate vaccines and the effect on Hib immunogenicity of combining 2 Hib vaccines (Hib-teta
232 d administration of Hib and DTaP vaccines on Hib immunogenicity and would be suitable for preclinical
235 ge, a cross-sectional study of oropharyngeal Hib carriage was conducted among Alaska Native children
237 E of strain Eagan also bound to all piliated Hib strains but did not bind to the piliated NTHI strain
238 the mature protein reacted more to piliated Hib than to nonpiliated Hib or to a mutant containing a
239 nti-Haemophilus influenzae b polysaccharide (Hib PS) antibodies elicited in elderly subjects followin
241 s influenzae type b capsular polysaccharide (Hib PS) could be studied at the molecular level with pha
243 utine childhood immunization program reduced Hib disease incidence among children younger than 5 year
244 ic in infants and have significantly reduced Hib infections in the United States, but require multipl
249 to the nasopharynx, where the three-stranded Hib pilus filaments provide a robust tether to withstand
251 fimbriae 2 + 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were compared to responses
254 of electron micrograph images, we show that Hib pili comprise a helix 70 A in diameter with threefol
259 to 1086327) and found to be the same for the Hib and two Hib(-) strains as well as some other encapsu
261 ssociated with reduced immunogenicity of the Hib component, although there is little agreement on the
262 d by shifts in the major VL component of the Hib PS-specific repertoire or by diminution of the prote
268 times their original length, while damage to Hib pili occurs by slight shearing of subunits with resp
269 odies than unexposed infants (n = 54) did to Hib (0.37 [interquartile range {IQR}, 0.22-0.67] mg/L vs
271 = 46) had lower specific antibody levels to Hib (0.67 [IQR, 0.16-1.54] mg/L vs 1.34 [IQR, 0.15-4.82]
272 ntly lower IgM concentrations in response to Hib (P<.05) and to both pneumococcal serotypes 14 (P<.00
273 ociated with the increased susceptibility to Hib disease among individuals carrying the A2b allele.
274 on also proliferated to proteinase K-treated Hib antigen, suggesting that it recognized a nonpeptide.
275 and found to be the same for the Hib and two Hib(-) strains as well as some other encapsulated divisi
276 ccine formulations given to fully vaccinated Hib cases with those administered to fully immunised age
277 ningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administered in the left leg at 12 months.
279 immunogenicity of combining 2 Hib vaccines (Hib-tetanus toxoid [TT]-A and Hib-TT-B) with diphtheria-
282 duction in the antibody response to PRP when Hib-TT-A was administered in combination with DTaP(3) an
283 vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccine and followed up to 43 and 72 month
284 vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccines, avidity increased in the period
290 nus-acellular pertussis (DTaP) combined with Hib-PS conjugated to tetanus toxoid (PRP-T) and hepatiti
291 y anti-Hib PS mAbs of infants immunized with Hib oligosaccharide-diphtheria toxin vaccine vaccine are
293 cell response, 19 adults were immunized with Hib-CRM(197), and antibody titers, carrier protein-speci
294 like most mAbs from adults, react only with Hib PS and the structurally similar PS of Escherichia co
295 unized subcutaneously with Hib alone or with Hib and DTaP-based vaccines; anti-Hib capsular polysacch
296 influenzae (NTHi) isolates were probed with Hib cap-gene-containing plasmid pUO38 and with IS1016; a
299 mentation of routine infant vaccination with Hib polysaccharide-tetanus protein conjugate (PRP-T) vac
300 Hib carriage in children aged 1 to <2 years, Hib antibody levels in children aged <5 years, and Hib v
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。